Equities analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report $2.89 earnings per share for the current quarter, Zacks reports. Seven analysts have made estimates for Jazz Pharmaceuticals PLC’s earnings. The highest EPS estimate is $3.00 and the lowest is $2.78. Jazz Pharmaceuticals PLC posted earnings per share of $2.57 during the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The business is scheduled to report its next earnings results on Tuesday, November 14th.

On average, analysts expect that Jazz Pharmaceuticals PLC will report full year earnings of $10.91 per share for the current fiscal year, with EPS estimates ranging from $10.74 to $11.05. For the next year, analysts anticipate that the company will report earnings of $12.98 per share, with EPS estimates ranging from $11.81 to $14.80. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same quarter in the previous year, the firm earned $2.67 EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis.

Several research analysts recently commented on the company. Sanford C. Bernstein set a $176.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “market perform” rating in a research report on Monday, May 22nd. Vetr upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective for the company in a research note on Tuesday, June 6th. Deutsche Bank AG reiterated a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Piper Jaffray Companies set a $182.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Friday, July 14th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $180.96.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 1.47% during mid-day trading on Thursday, reaching $150.79. 368,950 shares of the company’s stock traded hands. The stock has a market capitalization of $9.06 billion, a PE ratio of 23.23 and a beta of 1.13. The firm’s 50-day moving average price is $150.36 and its 200 day moving average price is $149.43. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75.

In other news, Director Paul L. Berns sold 662 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the transaction, the director now owns 6,599 shares in the company, valued at approximately $939,499.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick G. Enright sold 351 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $148.40, for a total value of $52,088.40. Following the transaction, the director now owns 1,717 shares in the company, valued at approximately $254,802.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,917 shares of company stock worth $1,223,227. Company insiders own 4.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals PLC by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after purchasing an additional 849,348 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals PLC by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after purchasing an additional 153,908 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Jazz Pharmaceuticals PLC by 3,163.9% during the 1st quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after purchasing an additional 3,116,652 shares in the last quarter. Janus Capital Management LLC lifted its holdings in shares of Jazz Pharmaceuticals PLC by 46.8% during the 1st quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after purchasing an additional 468,940 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Jazz Pharmaceuticals PLC by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after purchasing an additional 410,031 shares in the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/07/jazz-pharmaceuticals-plc-jazz-expected-to-post-earnings-of-2-89-per-share.html.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals PLC (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.